NCT00241111View on ClinicalTrials.gov

Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis

PHASE4CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2006

Conditions
Prostate Cancer With Bone Metastasis
Interventions
DRUG

zoledronic acid

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00241111 - Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis | Biotech Hunter | Biotech Hunter